RBC Europe’s Petros Pharmaceuticals PTPI Stock Holding History

RBC Europe’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9	Closed	-$7.99K	–	1252
2021 Q1	$7.99K	Hold	9	–	–	﹤0.01%	946
2020 Q4	$9.43K	Buy	+9	New	+$8.47K	﹤0.01%	888

Other funds holding PTPI

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

NorthRock Partners Minneapolis, Minnesota $6.2B AUM 15.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AFAS

Acorn Financial Advisory Services Reston, Virginia $753M AUM 36.94% 1-Year Est. Return

PTP

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's PTPI Position: Q2 2021 in Review

RBC Europe sold out of Petros Pharmaceuticals (PTPI) in Q2 2021, closing a stake of 9 shares — an estimated $7.99K sold.

RBC Europe first reported a position in PTPI in Q4 2020 and held it in 2 quarters. The position peaked at $9.43K in Q4 2020. 18 funds tracked by Wall St. Rank hold PTPI as of Q2 2021.

RBC Europe reported no remaining Petros Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
RBC Europe sold 9 Petros Pharmaceuticals shares in Q2 2021, an estimated $7.99K.
RBC Europe first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 2 quarters.
RBC Europe's Petros Pharmaceuticals position peaked at $9.43K in Q4 2020.
18 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2021.

Based on RBC Europe's 13F filing for Q2 2021, filed 9 Nov 2023.